- ChromaDex (NASDAQ:CDXC) has announced results from a Phase 2 study in patients with mild-to-moderate COVID-19 and reported a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including nicotinamide riboside.
- This additional nutritional support was designed to promote healthy mitochondrial function and reduced average recovery time to 6.6 days in comparison to average placebo recovery time of 9.3 days.
- Patients receiving the nutritional protocol consisting of nicotinamide riboside, L-serine, N-acetyl-L-cysteine, and L-carnitine tartrate also experienced a significant improvement in liver function
- Results from the study were published on the open access preprint publication server medRxiv.org.
Tuesday, October 6, 2020
Chromadex's study with nutritional protocol shows lower recovery time in COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.